MYC and triple-negative breast carcinoma: Interestingly, Carey et al. (2017) have recently demonstrated that the efficacy of PARP inhibitors in MYC-driven triple-negative breast cancer cells can be further increased by concomitant downregulation of MYC expression using the cyclin-dependent kinase inhibitor dinaciclib.